enhancin 375mg tablets film coated - Keresési eredmények

Európai Unió - magyar - EMA (European Medicines Agency)

skilarence

almirall s.a - dimetil-fumarát - pikkelysömör - immunszuppresszánsok - a skilarence a középsúlyos vagy súlyos plakkos psoriasis kezelésére javallt szisztémás gyógyterápiában szenvedő felnőtteknél.

Európai Unió - magyar - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumabot - szklerózis multiplex - szelektív immunszuppresszánsok - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Európai Unió - magyar - EMA (European Medicines Agency)

lumeblue (previously known as methylthioninium chloride cosmo)

alfasigma s.p.a. - metil-tionin-klorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Európai Unió - magyar - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod-hidroklorid - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 és 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Európai Unió - magyar - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumabot - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.